VIRO Stock Overview
An in vitro diagnostics company, develops and markets prognostic products for the healthcare sector. More details
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
ViroGates A/S Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | DKK 12.10 |
52 Week High | DKK 31.00 |
52 Week Low | DKK 5.20 |
Beta | 0.74 |
1 Month Change | -24.38% |
3 Month Change | 108.62% |
1 Year Change | 72.86% |
3 Year Change | -92.07% |
5 Year Change | -64.41% |
Change since IPO | -85.85% |
Recent News & Updates
Recent updates
ViroGates (CPH:VIRO) Is In A Good Position To Deliver On Growth Plans
Mar 06We're Hopeful That ViroGates (CPH:VIRO) Will Use Its Cash Wisely
Nov 21Will ViroGates (CPH:VIRO) Spend Its Cash Wisely?
Jun 14We're Not Very Worried About ViroGates' (CPH:VIRO) Cash Burn Rate
Sep 19We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth
Apr 14We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth
Dec 30Shareholder Returns
VIRO | DK Medical Equipment | DK Market | |
---|---|---|---|
7D | -14.2% | -3.8% | -4.2% |
1Y | 72.9% | 0.2% | 4.4% |
Return vs Industry: VIRO exceeded the Danish Medical Equipment industry which returned 0.2% over the past year.
Return vs Market: VIRO exceeded the Danish Market which returned 4.4% over the past year.
Price Volatility
VIRO volatility | |
---|---|
VIRO Average Weekly Movement | 26.2% |
Medical Equipment Industry Average Movement | 3.8% |
Market Average Movement | 4.2% |
10% most volatile stocks in DK Market | 10.5% |
10% least volatile stocks in DK Market | 2.6% |
Stable Share Price: VIRO's share price has been volatile over the past 3 months compared to the Danish market.
Volatility Over Time: VIRO's weekly volatility has increased from 17% to 26% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 10 | Jakob Knudsen | www.virogates.com |
ViroGates A/S, an in vitro diagnostics company, develops and markets prognostic products for the healthcare sector. It offers suPARnostic, a proprietary biomarker used in hospital emergency services to support the clinical decision on hospitalization or discharge of acute patients and to identify high-risk sepsis patients at an early stage, as well as used for the prognosis of lifestyle-related diseases, such as cardiovascular disease, type 2 diabetes, and cancer; and for the assessment of longevity and biological age in a non-hospital setting. The company’ products icludes suPARnostic TurbiLatex, a latex particle-enhanced turbidimetric immunoassay that quantitatively determines the soluble urokinase plasminogen activator receptor (suPAR) level in human K2-EDTA- or lithium heparin plasma samples; suPARnostic ELISA that provides fully quantitative results; suPARnostic Quick Triage kit, which is used in the point of care situation for early warning and patient triaging that will allow clinicians and nurses to obtain a fast patient prognosis for patient disease severity, progression and outcome; and suPARnostic POC+, a point-of-care finger prick test that detects the level of suPAR in the blood.
ViroGates A/S Fundamentals Summary
VIRO fundamental statistics | |
---|---|
Market cap | DKK 99.77m |
Earnings (TTM) | -DKK 13.23m |
Revenue (TTM) | DKK 7.25m |
12.9x
P/S Ratio-7.1x
P/E RatioIs VIRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VIRO income statement (TTM) | |
---|---|
Revenue | DKK 7.25m |
Cost of Revenue | DKK 1.80m |
Gross Profit | DKK 5.45m |
Other Expenses | DKK 18.69m |
Earnings | -DKK 13.23m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 20, 2025
Earnings per share (EPS) | -1.71 |
Gross Margin | 75.22% |
Net Profit Margin | -182.57% |
Debt/Equity Ratio | 74.8% |
How did VIRO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/20 17:53 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ViroGates A/S is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|